Obstetrics and GynecologyObstetrics and GynecologyАкушерство и гинекология0300-90922412-5679Bionika Media32969210.18565/aig.2017.6.10-6ArticlesСтатьиReview ArticleEMERGENCY AND ELECTIVE SURGICAL MANAGEMENT OF TUMORS OF THE UTERINE APPENDAGESЭКСТРЕННОЕ И ПЛАНОВОЕ ХИРУРГИЧЕСКОЕ ЛЕЧЕНИЕ НОВООБРАЗОВАНИЙ ПРИДАТКОВ МАТКИNikogosyanSeda OvikovnaНикогосянСеда Овиковна

MD, Ph.D., Department of Oncogynecology

д.м.н., в.н.с. отделения онкогинекологии

KuznetsovViktor VasilievichКузнецовВиктор Васильевич

MD, professor, head of the Department of Oncogynecology; member of the Moscow Society of Oncologists; member of the International Gynecologic Cancer Society

д.м.н., профессор, зав. отделением онкогинекологии; член Московского общества онкологов, член Международного общества онкогинекологов (International Gynecologic Cancer Society).

ZagashtokovAslan ZamakhshariyevichЗагаштоковАслан Замахшариевич

aspirant of the Department of Oncogynecology

аспират отделения онкогинекологии

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaФГБУ РОНЦ им. Н.Н. Блохина Минздрава России151220176NO6 (2017)№6 (2017)101714042023Copyright ©; 2017, Bionika MediaCopyright ©; 2017, ООО «Бионика Медиа»2017Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/0300-9092/article/view/329692

Objective. To discuss the clinical aspects of differential diagnosis and treatment policy in patients with ovarian tumors, as well as indications for emergency and elective surgery. Material and methods. The review included the data of foreign and Russian articles published in the past 20 years and found in international databases on this topic. Results. The most significant risk factors for ovarian cancer are a family history, age, hormone replacement therapy, endometriosis, and obesity. Differential diagnosis is based on the data of transvaginal ultrasound in terms of the International Ovarian Tumor Analysis (IONA) diagnostic criteria and on the determination of the level of the markers CA 125, HE4, lactate dehydrogenase, human chorionic gonadotropin, and α-fetoprotein. The optimal method of surgical intervention is laparoscopic surgery, with intraoperative and elective histological examination. Conclusion. When diagnosing malignant ovarian tumor, the latter should be treated only in specialized clinics.

Цель исследования. Обсудить клинические аспекты дифференциальной диагностики и лечебной тактики в отношении пациенток с новообразованиями яичников, показания к экстренным и плановым хирургическим вмешательствам. Материал и методы. В обзор включены данные зарубежных и отечественных статей, найденных в международных базах данных по данной теме, опубликованных за последние 20лет. Результаты. Наиболее значимыми факторами риска развития рака яичников являются семейный анамнез, возраст, использование заместительной гормональной терапии, эндометриоз и ожирение. Дифференциальная диагностика основывается на данных трансвагинального ультразвукового исследования с учетом диагностических критериев IOTA,определение уровня маркеров CA 125, HE4, ЛДГ, ХГЧ, АФП. Оптимальным методом хирургического вмешательства является лапароскопическая операция с интраоперационным и плановым гистологическим исследованием. Заключение. При постановке диагноза злокачественной опухоли яичников лечение должно проводиться только в условиях специализированных клиник.

ovarian neoplasmdiagnosissurgical treatmentновообразование яичникадиагностикахирургическое лечениеSant M., Aareleid T, Berrino F., Bielska Lasota M., Carli P.M. et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary. Ann. Oncol. 2003; 14(Suppl. 5): v61-118.Royal College of Obstetricians and Gynaecologists. Management of suspected ovarian masses in premenopausal women. Green-Top Guideline. No 62. London: RCOG; 2011.Myers E.R., Bastian L.A., Havrilesky L.J., Kulasingam S.L., Terplan M.S., Cline K.E. et al. Management of adnexal mass. Evid. Rep. Technol. Assess. (Full Rep). 2006; (130): 1-145.Hartge P., Hayes R., Reding D., Sherman M.E., Prorok P., Schiffman M. et al. Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial. Am. J. Obstet. Gynecol. 2000; 183(5): 1232-7.Teichmann A.T., Brill K., Albring M., Schnitker J., Wojtynek P., Kustra E. The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth. Gynecol. Endocrinol. 1995; 9(4): 299-305.Argenta P.A., Yeagley T.J., Ott G., Sondheimer S.J. Torsion of the uterine adnexa. Pathologic correlations and current management trends. J. Reprod. Med. 2000; 45(10): 831-6.Sommerville M., Grimes D.A., Koonings P.P., Campbell K. Ovarian neoplasms and the risk of adnexal torsion. Am. J. Obstet. Gynecol. 1991; 164(2): 577-8.MacKenna A., Fabres C., Alam V., Morales V. Clinical management of functional ovarian cysts: a prospective and randomized study. Hum. Reprod. 2000; 15(12): 2567-9.Abduljabbar H.S., Bukhari Y.A., Al Hachim E.G., Alshour G.S., Amer A.A., Shaikhoon M.M., Khojah M.I. Review of 244 cases of ovarian cysts. Saudi Med. J. 2015; 36(7): 834-8.Bailey C.L., Ueland F.R., Land G.L., DePriest P.D., Gallion H.H., Kryscio R.J. et al. The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol. Oncol. 1998; 69(1): 3-7.Farghaly S.A. Current diagnosis and management of ovarian cysts. Clin. Exp. Obstet. Gynecol. 2014; 41(6): 609-12.Doeksen A., Bakx R., Vincent A., van Tets W.F., Sprangers M.A., Gerhards M.F. et al. J-pouch vs side-to-end coloanal anastomosis after preoperative radiotherapy and total mesorectal excision for rectal cancer: a multicentre randomized trial. Colorectal Dis. 2012; 14(6): 705-13.Zhang S., Royer R., Li S., McLaughlin J.R., Rosen B., Risch H.A. et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol. Oncol. 2011; 121(2): 353-7.Thibodeau S.N., French A.J., Cunningham J.M., Tester D., Burgart L.J., Roche P.C. et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res. 1998; 58(8): 1713-8.Beral V., Doll R., Hermon C., Peto R., Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008; 371(9609): 303-14.Cibula D., Widschwendter M., Majek O., Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum. Reprod. Update. 2011; 17(1): 55-67.Breastfeeding and the risk of ovarian cancer: a meta-analysis. J. Midwifery Womens Health. 2015; 60(3): 337.Jacobs I.J., Menon U., Ryan A., Gentry-Maharaj A., Burnell M., Kalsi J.K. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016; 387(10022): 945-56.Dodge J.E., Covens A.L., Lacchetti C., Elit L.M., Le T., Devries M. et al. Management of a suspicious adnexal mass: a clinical practice guideline. Curr. Oncol. 2012; 19(4): e244-57.Alcazar J.L., Castillo G. Comparison of 2-dimensional and 3-dimensional power-Doppler imaging in complex adnexal masses for the prediction of ovarian cancer. Am. J. Obstet. Gynecol. 2005; 192(3): 807-12.Booth S.J., Turnbull L.W., Poole D.R., Richmond I. The accurate staging of ovar ian cancer using 3T magnetic resonance imaging-- a realistic option. BJOG. 2008; 115(7): 894-901.DePriest P.D., Shenson D., Fried A., Hunter J.E., Andrews S.J., Gallion H.H. et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol. Oncol. 1993; 51(1): 7-11.Ferrazzi E., Zanetta G., Dordoni D., Berlanda N., Mezzopane R., Lissoni A.A. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study. Ultrasound Obstet. Gynecol. 1997; 10(3): 192-7.Timmerman D., Testa A.C., Bourne T., Ferrazzi E., Ameye L., Konstantinovic M.L. et al. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J. Clin. Oncol. 2005; 23(34): 8794-801.Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J.G. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br. J. Obstet. Gynaecol. 1990; 97(10): 922-9.Asif N., Sattar A., Dawood M.M., Rafi T., Aamir M., Anwar M. Pre-operative evaluation of ovarian mass: risk of malignancy index. J. Coll. Physicians Surg. Pak. 2004; 14(3): 128-31.Morgante G., la Marca A., Ditto A., De Leo V. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br. J. Obstet. Gynaecol. 1999; 106(6): 524-7.ACOG Practice Bulletin. Management of adnexal masses. Obstet. Gynecol. 2007; 110(1): 201-14.NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 1995; 273(6): 491-7.Kahraman K., Ozguven I., Gungor M., Somer C.A. Extremely elevated serum CA-125 level as a result of unruptured unilateral endometrioma: the highest value reported. Fertil. Steril. 2007; 88(4): 968. e15-7.Van Calster B., Timmerman D., Bourne T., Testa A.C., Van Holsbeke C., Domali E. et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J. Natl. Cancer Inst. 2007; 99(22): 1706-14.Chang X., Ye X., Dong L., Cheng H., Cheng Y., Zhu L. et al. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int. J. Gynecol. Cancer. 2011; 21(5): 852-8.Li F., Tie R., Chang K., Wang F., Deng S., Lu W. et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer. 2012; 12: 258.Bottomley C., Bourne T. Diagnosis and management of ovarian cyst accidents. Best Pract. Res. Clin. Obstet. Gynaecol. 2009; 23(5): 711-24.Kim J.H., Lee S.M., Lee J.-H., Jo Y.R., Moon M.H., Shin J. et al. Successful conservative management of ruptured ovarian cysts with hemoperitoneum in healthy women. PLoS One. 2014; 9(3): e91171.Chiou S.Y., Lev-Toaff A.S., Masuda E., Feld R.I., Bergin D. Adnexal torsion: new clinical and imaging observations by sonography, computed tomography, and magnetic resonance imaging. J. Ultrasound Med. 2007; 26(10): 1289-301.Yuen P.M., Yu K.M., Yip S.K., Lau W.C., Rogers M.S., Chang A. A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am. J. Obstet. Gynecol. 1997; 177(1): 109-14.Panici P.B., Muzii L., Palaia I., Manci N., Beüati F., Plotti F. et al. Minilaparotomy versus laparoscopy in the treatment of benign adnexal cysts: a randomized clinical study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007; 133(2): 218-22.Fanfani F., Fagotti A., Ercoli A., Bifulco G., Longo R., Mancuso S. et al. A prospective randomized study of laparoscopy and minilaparotomy in the management of benign adnexal masses. Hum. Reprod. 2004; 19(10): 2367-71.Bourdel N., Matsuzaki S., Bazin J.-E., Darcha C., Pouly J.-L., Mage G. et al. Postoperative peritoneal dissemination of ovarian cancer cells is not promoted by carbon-dioxide pneumoperitoneum at low intraperitoneal pressure in a syngenic mouse laparoscopic model with controlled respiratory support: a pilot study. J. Minim. Invasive Gynecol. 2008; 15(3): 321-6.Aoki D. Laparoscopic surgery for early ovarian cancer. J. Gynecol. Oncol. 2014; 25(3): 168-9.Desfeux P., Camatte S., Chatellier G., Blanc B., Querleu D., Lecuru F. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol. Oncol. 2005; 98(3): 390-5.Park J.Y., Kim D.Y., Kim J.H., Kim Y.M., Kim Y.T., Nam J.H. Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery. Gynecol. Oncol. 2009; 113(1): 75-82.Ghezzi F., Cromi A., Uccella S., Bergamini V., Tomera S., Franchi M. et al. Laparoscopy versus laparotomy for the surgical management of apparent early stage ovarian cancer. Gynecol. Oncol. 2007; 105(2): 409-13.Park J.Y., Bae J., Lim M.C., Lim S.Y., Seo S.S., Kang S. et al. Laparoscopic and laparotomic staging in stage I epithelial ovarian cancer: a comparison of feasibility and safety. Int. J. Gynecol. Cancer. 2008; 18(6): 1202-9.Zhang Y., Fan S., Xiang Y., Duan H., Sun L. Comparison of the prognosis and recurrence of apparent early-stage ovarian tumors treated with laparoscopy and laparotomy: a meta-analysis of clinical studies. BMC Cancer. 2015; 15: 597.Моисеенко Т.И., Неродо Г.А. Последствия лапароскопических операций у больных с начальными стадиями рака яичников. В кн.: Органосохраняющие и реконструктивные операции у больных злокачественными опухолями. Сборник статей. М.; 2007: 215-22Vernooij F., Heintz A.P., Witteveen P.O., van der Heiden-van der Loo M., Coebergh J.W., van der Graaf Y. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study. J. Natl. Cancer Inst. 2008; 100(6): 399-406.Новикова Е.Г., Сухина Н.Г., Иванов В.П. Ошибки в диагностике и лечении редких форм злокачественных опухолей яичников, выявленных при лапароскопии. В кн.: Материалы VI Российской онкологической конференции. 26-28 ноября 2002 года, Москва. Электронный ресурс: http://www.roson-coweb.ruMinig L., Padilla-Iserte P., C. Zorrero C. The relevance of gynecologic oncologists to provide high-quality of care to women with gynecological cancer. Front. Oncol. 2016; 5: 308